Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy

Summary

This comparative effectiveness study aimed to evaluate healthcare resource utilization (HRU) and costs associated with rivaroxaban and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and polypharmacy. To achieve this, IQVIA PharMetrics^® Plus (January 2010–September 2019) data were used to identify NVAF patients with obesity  and polypharmacy initiated on rivaroxaban or warfarin. Weighted rate ratios and cost differences were evaluated post-treatment initiation. Subsequently, it was found that rivaroxaban was associated with significantly lower rates of HRU, including hospitalization. Medical costs were reduced in rivaroxaban users, resulting in significantly lower total healthcare costs compared with warfarin users. As a result, rivaroxaban was associated with lower HRU and costs compared with warfarin among NVAF patients with obesity and polypharmacy in commercially insured US patients.